Telix Pharmaceuticals’ (TLX) Buy Rating Reiterated at HC Wainwright

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $20.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 86.57% from the stock’s current price.

A number of other research firms have also recently commented on TLX. Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Wedbush reissued an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Wednesday, September 23rd. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, September 21st. Finally, Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Telix Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $20.50.

Telix Pharmaceuticals Stock Down 2.3%

TLX traded down $0.25 during trading on Friday, reaching $10.72. The stock had a trading volume of 201,696 shares, compared to its average volume of 226,954. The stock’s 50 day moving average is $11.40 and its two-hundred day moving average is $10.59. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $13.11.

Institutional Investors Weigh In On Telix Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Bank of America Corp DE boosted its position in shares of Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after buying an additional 8,423 shares during the last quarter. XY Capital Ltd purchased a new stake in shares of Telix Pharmaceuticals during the first quarter valued at $120,000. Private Advisor Group LLC boosted its position in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares during the last quarter. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of Telix Pharmaceuticals during the second quarter valued at $1,731,000. Finally, Lazard Asset Management LLC boosted its position in shares of Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after buying an additional 39,400 shares during the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its technologies are designed to help identify disease through medical imaging and, in some cases, deliver radiation directly to targeted cancer cells.

The company’s primary commercial product is Illuccix (kit for the preparation of gallium-68 gozetotide injection), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in adults with prostate cancer.